1.Luttun, A, Carmeliet, P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest 2003; 111 (5): 600–2.
2.Barleon, B, Reusch, P, Totzke, F, Herzog, C, Keck, C, Martiny-Baron, G, et al.Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 2001; 4 (2): 143–54.
3.Clark, DE, Smith, SK, He, Y, Day, KA, Licence, DR, Corps, AN, et al.A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59 (6): 1540–48.
4.Levine, RJ, Maynard, SE, Qian, C, Lim, KH, England, LJ, Yu, KF, et al.Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350 (7): 672–83.
5.Levine, RJ, Karumanchi, SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005; 48 (2): 372–86.
6.Maynard, SE, Min, JY, Merchan, J, Lim, KH, Li, J, Mondal, S, et al.Excess placental soluble FMS-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111 (5): 649–58.
7.Venkatesha, S, Toporsian, M, Lam, C, Hanai, J, Mammoto, T, Kim, YM, et al.Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12 (6): 642–9.
8.Ferrara, N, Gerber, HP, LeCouter, J. The biology of VEGF and its receptors. Nat Med 2003; 9 (6): 669–76.
9.Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25 (4): 581–611.
10.Torry, DS, Wang, HS, Wang, TH, Caudle, MR, Torry, RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998; 179 (6, Pt 1): 1539–44.
11.Koga, K, Osuga, Y, Yoshino, O, Hirota, Y, Ruimeng, X, Hirata, T, et al.Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88 (5): 2348–51.
12.Krauss, T, Pauer, HU, Augustin, HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23 (1): 101–11.
13.Chaiworapongsa, T, Romero, R, Kim, YM, Kim, GJ, Kim, MR, Espinoza, J, et al.Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17 (1): 3–18.
14.Redman, CW, Sargent, IL. Latest advances in understanding preeclampsia. Science 2005; 308 (5728): 1592–94.
15.Bdolah, Y, Karumanchi, SA, Sachs, BP. Recent advances in understanding of preeclampsia. Croat Med J 2005; 46 (5): 728–36.
16.Robinson, CJ, Johnson, DD, Chang, EY, Armstrong, DM, Wang, W. Evaluation of placenta growth factor and soluble FMS-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006; 195 (1): 255–9.
17.Crispi, F, Dominguez, C, Llurba, E, Martin-Gallan, P, Cabero, L, Gratacos, E. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006; 195 (1): 201–7.
18.Levine, RJ, Lam, C, Qian, C, Yu, KF, Maynard, SE, Sachs, BP, et al.Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355 (10): 992–1005.
19.Boutsikou, T, Malamitsi-Puchner, A, Economou, E, Boutsikou, M, Puchner, KP, Hassiakos, D. Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. Early Hum Dev 2006; 82 (4): 235–9.
20.Wallner, W, Sengenberger, R, Strick, R, Strissel, PL, Meurer, B, Beckmann, MW, et al.Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 2007; 112 (1): 51–7.
21.Espinoza, J, Romero, R, Nien, JK, Kusanovic, JP, Richani, K, Gomez, R, et al.A role of the anti-angiogenic factor sVEGFR-1 in the “mirror syndrome” (Ballantyne's syndrome). J Matern Fetal Neonatal Med 2006; 19 (10): 607–13.
22.Rana, S, Venkatesha, S, DePaepe, M, Chien, EK, Paglia, M, Karumanchi, SA. Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol 2007; 109 (2, Pt2): 549–52.
23.Kusanovic, JP, Romero, R, Espinoza, J, Nien, JK, Kim, CJ, Mittal, P, et al.Twin-to-twin transfusion syndrome: an antiangiogenic state? Am J Obstet Gynecol 2008; 198 (4): 382–8.
24.Espinoza, J, Chaiworapongsa, T, Romero, R, Kim, YM, Kim, GJ, Nien, JK, et al.Unexplained fetal death: another anti-angiogenic state. J Matern Fetal Neonatal Med 2007; 20 (7): 495–507.
25.Espinoza, J, Uckele, JE, Starr, RA, Lorenz, RP, Bronsteen, RA, Berry, SM. Insights into angiogenic imbalances during pregnancy. Obstet Gynecol 2009; 114: 437–440.
26.Zhou, Y, McMaster, M, Woo, K, Janatpour, M, Perry, J, Karpanen, T, et al.Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160 (4): 1405–23.
27.Tsatsaris, V, Goffin, F, Munaut, C, Brichant, JF, Pignon, MR, Noel, A, et al.Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88 (11): 5555–63.
28.Aggarwal, PK, Jain, V, Sakhuja, V, Karumanchi, SA, Jha, V. Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int 2006; 69 (3): 621–4.
29.Signore, C, Mills, JL, Qian, C, Yu, K, Lam, C, Epstein, FH, et al.Circulating angiogenic factors and placental abruption. Obstet Gynecol 2006; 108 (2): 338–44.
30.Stepan, H, Faber, R. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med 2006; 354 (17): 1857–58.
31.Kallen, B. Maternal morbidity and mortality in in-vitro fertilization. Best Pract Res Clin Obstet Gynaecol 2008; 22 (3): 549–58.
32.Kallen, B, Finnstrom, O, Nygren, KG, Otterblad, OP, Wennerholm, UB. In vitro fertilisation in Sweden: obstetric characteristics, maternal morbidity and mortality. BJOG 2005; 112 (11): 1529–35.
33.Gilbert, JS, Babcock, SA, Granger, JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble FMS-like tyrosine kinase-1 expression. Hypertension 2007; 50 (6): 1142–47.
34.Lyall, F, Greer, IA, Boswell, F, Fleming, R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 1997; 104 (2): 223–228.
35.Kupferminc, MJ, Daniel, Y, Englender, T, Baram, A, Many, A, Jaffa, AJ, et al.Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol 1997; 38 (4): 302–306.
36.McKeeman, GC, Ardill, JE, Caldwell, CM, Hunter, AJ, McClure, N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191 (4): 1240–1246.
37.Chaiworapongsa, T, Romero, R, Espinoza, J, Bujold, E, Mee, KY, Goncalves, LF, et al.Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young investigator award. Am J Obstet Gynecol 2004; 190 (6): 1541–47.
38.Maynard, SE, Venkatesha, S, Thadhani, R, Karumanchi, SA. Soluble FMS-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 2005; 57 (5, Pt 2): 1R–7R.
39.Levine, RJ, Thadhani, R, Qian, C, Lam, C, Lim, KH, Yu, KF, et al.Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293 (1): 77–85.
40.Rajakumar, A, Michael, HM, Rajakumar, PA, Shibata, E, Hubel, CA, Karumanchi, SA, et al.Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1) by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005; 26 (7): 563–73.
41.Shibata, E, Rajakumar, A, Powers, RW, Larkin, RW, Gilmour, C, Bodnar, LM, et al.Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90 (8): 4895–4903.
42.Staff, AC, Braekke, K, Harsem, NK, Lyberg, T, Holthe, MR. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2005; 122 (1): 33–9.
43.Steegers, EA, von Dadelszen, P, Duvekot, JJ, Pijnenborg, R. Pre-eclampsia. Lancet 2010; 376 (9741): 631–44.
44.von Dadelszen, P, Magee, LA, Roberts, JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003; 22 (2): 143–8.
45.Dekker, GA, Sibai, BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998; 179 (5): 1359–75.
46.Austgulen, R, Isaksen, CV, Chedwick, L, Romundstad, P, Vatten, L, Craven, C. Pre-eclampsia: associated with increased syncytial apoptosis when the infant is small-for-gestational-age. J Reprod Immunol 2004; 61 (1): 39–50.
47.Crocker, IP, Cooper, S, Ong, SC, Baker, PN. Differences in apoptotic susceptibility of cytotrophoblasts and syncytiotrophoblasts in normal pregnancy to those complicated with preeclampsia and intrauterine growth restriction. Am J Pathol 2003; 162 (2): 637–43.
48.Leung, DN, Smith, SC, To, KF, Sahota, DS, Baker, PN. Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 2001; 184 (6): 1249–50.
49.Sargent, IL, Germain, SJ, Sacks, GP, Kumar, S, Redman, CW. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 2003; 59 (2): 153–60.
50.Johansen, M, Redman, CW, Wilkins, T, Sargent, IL. Trophoblast deportation in human pregnancy – its relevance for pre-eclampsia. Placenta 1999; 20 (7): 531–9.
51.Knight, M, Redman, CW, Linton, EA, Sargent, IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol 1998; 105 (6): 632–40.
52.Chua, S, Wilkins, T, Sargent, I, Redman, C. Trophoblast deportation in pre-eclamptic pregnancy. Br J Obstet Gynaecol 1991; 98 (10): 973–9.
53.Makris, A, Thornton, C, Thompson, J, Thomson, S, Martin, R, Ogle, R, et al.Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007; 71 (10): 977–84.
54.Nagamatsu, T, Fujii, T, Kusumi, M, Zou, L, Yamashita, T, Osuga, Y, et al.Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004; 145 (11): 4838–45.
55.Nevo, O, Soleymanlou, N, Wu, Y, Xu, J, Kingdom, J, Many, A, et al.Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006; 291 (4): R1085–R93.
56.Chaiworapongsa, T, Espinoza, J, Gotsch, F, Kim, YM, Kim, GJ, Goncalves, LF, et al.The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008; 21 (1): 25–40.
57.Soto, E, Romero, R, Kusanovic, JP, Ogge, G, Hussein, Y, Yeo, L, et al.Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med 2011; 25: 498–507.
58.Espinoza, J, Uckele, JE, Starr, RA, Seubert, DE, Espinoza, AF, Berry, SM. Angiogenic imbalances: the obstetric perspective. Am J Obstet Gynecol 2010; 203 (1): 17–18.
59.Rajakumar, A, Cerdeira, AS, Rana, S, Zsengeller, Z, Edmunds, L, Jeyabalan, A, et al.Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension 2012; 59 (2): 256–64.
60.Rana, S, Schnettler, WT, Powe, C, Wenger, J, Salahuddin, S, Cerdeira, AS, et al.Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 2013; 32 (2): 189–201.
61.Malamitsi-Puchner, A, Boutsikou, T, Economou, E, Sarandakou, A, Makrakis, E, Hassiakos, D, et al.Vascular endothelial growth factor and placenta growth factor in intrauterine growth-restricted fetuses and neonates. Mediators Inflamm 2005; 2005 (5): 293–7.
62.Girardi, G, Yarilin, D, Thurman, JM, Holers, VM, Salmon, JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203 (9): 2165–75.
63.Padavala, S, Pope, N, Baker, P, Crocker, I. An imbalance between vascular endothelial growth factor and its soluble receptor in placental villous explants of intrauterine growth-restricted pregnancies. J Soc Gynecol Investig 2006; 13 (1): 40–7.
64.Sandrim, VC, Palei, AC, Cavalli, RC, Araujo, FM, Ramos, ES, Duarte, G, et al.Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. Mol Hum Reprod 2009; 15 (2): 115–20.
65.Tjoa, ML, van Vugt, JM, Mulders, MA, Schutgens, RB, Oudejans, CB, van Wijk, IJ. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001; 98 (4): 600–7.
66.Tidwell, SC, Ho, HN, Chiu, WH, Torry, RJ, Torry, DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184 (6): 1267–72.
67.Chappell, LC, Seed, PT, Briley, A, Kelly, FJ, Hunt, BJ, Charnock-Jones, DS, et al.A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002; 187 (1): 127–36.
68.Taylor, RN, Grimwood, J, Taylor, RS, McMaster, MT, Fisher, SJ, North, RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188 (1): 177–82.
69.Polliotti, BM, Fry, AG, Saller, DN, Mooney, RA, Cox, C, Miller, RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003; 101 (6): 1266–74.
70.Parra, M, Rodrigo, R, Barja, P, Bosco, C, Fernandez, V, Munoz, H, et al.Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am J Obstet Gynecol 2005; 193 (4): 1486–91.
71.Moore Simas, TA, Crawford, SL, Solitro, MJ, Frost, SC, Meyer, BA, Maynard, SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007; 197 (3): 244–8.
72.Ohkuchi, A, Hirashima, C, Matsubara, S, Suzuki, H, Takahashi, K, Arai, F, et al.Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res 2007; 30 (2): 151–9.
73.Poon, LC, Zaragoza, E, Akolekar, R, Anagnostopoulos, E, Nicolaides, KH. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 2008; 28 (12): 1110–15.
74.Erez, O, Romero, R, Espinoza, J, Fu, W, Todem, D, Kusanovic, JP, et al.The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21 (5): 279–87.
75.Poon, LC, Kametas, NA, Maiz, N, Akolekar, R, Nicolaides, KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53 (5): 812–18.
76.Thadhani, R, Mutter, WP, Wolf, M, Levine, RJ, Taylor, RN, Sukhatme, VP, et al.First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89 (2): 770–5.
77.Rana, S, Karumanchi, SA, Levine, RJ, Venkatesha, S, Rauh-Hain, JA, Tamez, H, et al.Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50 (1): 137–42.
78.Baumann, MU, Bersinger, NA, Mohaupt, MG, Raio, L, Gerber, S, Surbek, DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008; 199 (3): 266.
79.Romero, R, Nien, JK, Espinoza, J, Todem, D, Fu, W, Chung, H, et al.A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21 (1): 9–23.
80.Schmidt, M, Dogan, C, Birdir, C, Kuhn, U, Gellhaus, A, Kimmig, R, et al.Placental growth factor: a predictive marker for preeclampsia? Gynakol Geburtshilfliche Rundsch 2009; 49 (2): 94–99.
81.Espinoza, J, Romero, R, Nien, JK, Gomez, R, Kusanovic, JP, Goncalves, LF. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007; 196 (4): 326.e1–13.
82.Espinoza, J. Recent biomarkers for the identification of patients at risk for preeclampsia: the role of uteroplacental ischemia. Expert Opin Med Diagn 2012; 6 (2): 109–20.
83.Rasmussen, S, Irgens, LM. Fetal growth and body proportion in preeclampsia. Obstet Gynecol 2003; 101 (3): 575–83.
84.Aardema, MW, Saro, MC, Lander, M, De Wolf, BT, Oosterhof, H, Aarnoudse, JG. Second trimester Doppler ultrasound screening of the uterine arteries differentiates between subsequent normal and poor outcomes of hypertensive pregnancy: two different pathophysiological entities? Clin Sci (Lond) 2004; 106 (4): 377–82.
85.Harrington, K, Cooper, D, Lees, C, Hecher, K, Campbell, S. Doppler ultrasound of the uterine arteries: the importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby. Ultrasound Obstet Gynecol 1996; 7 (3): 182–88.
86.Albaiges, G, Missfelder-Lobos, H, Lees, C, Parra, M, Nicolaides, KH. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks’ gestation. Obstet Gynecol 2000; 96 (4): 559–64.
87.Papageorghiou, AT, Yu, CK, Cicero, S, Bower, S, Nicolaides, KH. Second-trimester uterine artery Doppler screening in unselected populations: a review. J Matern Fetal Neonatal Med 2002; 12 (2): 78–88.
88.Papageorghiou, AT, Yu, CK, Bindra, R, Pandis, G, Nicolaides, KH. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001; 18 (5): 441–449.
89.Moldenhauer, JS, Stanek, J, Warshak, C, Khoury, J, Sibai, B. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003; 189 (4): 1173–1177.
90.Ogge, G, Chaiworapongsa, T, Romero, R, Hussein, Y, Kusanovic, JP, Yeo, L, et al.Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia*. J Perinat Med 2011; 39 (6): 641–52.
91.Bolin, M, Wiberg-Itzel, E, Wikstrom, AK, Goop, M, Larsson, A, Olovsson, M, et al.Angiopoietin-1/angiopoietin-2 ratio for prediction of preeclampsia. Am J Hypertens 2009; 22 (8): 891–895.
92.Kusanovic, JP, Romero, R, Chaiworapongsa, T, Erez, O, Mittal, P, Vaisbuch, E, et al.A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009; 22 (11): 1021–38.
93.Poon, LC, Maiz, N, Valencia, C, Plasencia, W, Nicolaides, KH. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009; 33 (1): 23–33.
94.Chaiworapongsa, T, Romero, R, Savasan, ZA, Kusanovic, JP, Ogge, G, Soto, E, et al.Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011; 24 (10): 1187–207.
95.Stepan, H, Schaarschmidt, W, Jank, A, Verlohren, S, Kratzsch, J. Use of angiogenic factors (sFlt-1/PlGF ratio) to confirm the diagnosis of preeclampsia in clinical routine: first experience. Z Geburtshilfe Neonatol 2010; 214 (6): 234–38.
96.Rana, S, Powe, CE, Salahuddin, S, Verlohren, S, Perschel, FH, Levine, RJ, et al.Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125 (7): 911–9.
97.Verlohren, S, Herraiz, I, Lapaire, O, Schlembach, D, Zeisler, H, Calda, P, et al.New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2013; 63 (2): 346–52.
98.Lindheimer, MD, Kanter, D. Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. Obstet Gynecol 2010; 115 (2, Pt 1): 365–75.
99.Benton, SJ, Hu, Y, Xie, F, Kupfer, K, Lee, SW, Magee, LA, et al.Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol 2011; 205 (5): 469–8.
100.Sunderji, S, Gaziano, E, Wothe, D, Rogers, LC, Sibai, B, Karumanchi, SA, et al.Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010; 202 (1): 40–7.
101.Verlohren, S, Herraiz, I, Lapaire, O, Schlembach, D, Moertl, M, Zeisler, H, et al.The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206 (1): 58.
102.Knudsen, UB, Kronborg, CS, von Dadelszen, P, Kupfer, K, Lee, S, Vittinghus, E, et al.A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertens 2012; 2: 8–15.
103.Chappell, LC, Duckworth, S, Seed, PT, Griffin, M, Myers, J, Mackillop, L, et al.Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013; 128 (19): 2121–31.
104.Espinoza, J, Kusanovic, JP, Bahado-Singh, R, Gervasi, MT, Romero, R, Lee, W, et al.Should bilateral uterine artery notching be used in the risk assessment for preeclampsia, small-for-gestational-age, and gestational hypertension? J Ultrasound Med 2010; 29 (7): 1103–15.
105.O’driscoll, DT. A fluid retention syndrome associated with severe iso-immunization to the rhesus factor. J Obstet Gynaecol Br Emp 1956; 63 (3): 372–74.
106.Goodlin, RC. Impending fetal death in utero due to isoimmunization. Obstet Gynecol 1957; 10 (3): 299–302.
107.Scott, JS. Pregnancy toxaemia associated with hydrops foetalis, hydatidiform mole and hydramnios. J Obstet Gynaecol Br Emp 1958; 65 (5): 689–701.
108.Cohen, A. Maternal syndrome in Rh iso-immunization: report of a case. J Obstet Gynaecol Br Emp 1960; 67: 325–27.
109.Hirsch, MR, Mark, MS. Pseudotoxemia and erythroblastosis. Report of a case. Obstet Gynecol 1964; 24: 47–8.
110.John, AH, Duncan, AS. The Maternal Syndrome associated with hydrops foetalis. J Obstet Gynaecol Br Commonw 1964; 71: 61–5.
111.Quagliarello, JR, Passalaqua, AM, Greco, MA, Zinberg, S, Young, BK. Ballantyne's triple edema syndrome: prenatal diagnosis with ultrasound and maternal renal biopsy findings. Am J Obstet Gynecol 1978; 132 (5): 580–81.
112.Duthie, SJ, Walkinshaw, SA. Parvovirus associated fetal hydrops: reversal of pregnancy-induced proteinuric hypertension by in utero fetal transfusion. Br J Obstet Gynaecol 1995; 102 (12): 1011–13.
113.Carbillon, L, Oury, JF, Guerin, JM, Azancot, A, Blot, P. Clinical biological features of Ballantyne syndrome and the role of placental hydrops. Obstet Gynecol Surv 1997; 52 (5): 310–14.
114.Ordorica, SA, Marks, F, Frieden, FJ, Hoskins, IA, Young, BK. Aneurysm of the vein of Galen: a new cause for Ballantyne syndrome. Am J Obstet Gynecol 1990; 162 (5): 1166–67.
115.Midgley, DY, Harding, K. The Mirror syndrome. Eur J Obstet Gynecol Reprod Biol 2000; 88 (2): 201–2.
116.Finamore, PS, Kontopoulos, E, Price, M, Giannina, G, Smulian, JC. Mirror syndrome associated with sacrococcygeal teratoma: a case report. J Reprod Med 2007; 52 (3): 225–7.
117.Dorman, SL, Cardwell, MS. Ballantyne syndrome caused by a large placental chorioangioma. Am J Obstet Gynecol 1995; 173 (5): 1632–33.
118.Barker, G, Boyd, RD, D’Souza, SW, Donnai, P, Fox, H, Sibley, CP. Placental water content and distribution. Placenta 1994; 15 (1): 47–56.
119.Kovalovszki, L, Villanyi, E, Benko, G. Placental villous edema: a possible cause of antenatal hypoxia. Acta Paediatr Hung 1990; 30 (2): 209–15.
120.Naeye, RL, Maisels, MJ, Lorenz, RP, Botti, JJ. The clinical significance of placental villous edema. Pediatrics 1983; 71 (4): 588–94.
121.Alvarez, H, Sala, MA, Benedetti, WL. Intervillous space reduction in the edematous placenta. Am J Obstet Gynecol 1972; 112 (6): 819–20.
122.Stepan, H, Faber, R. Cytomegalovirus-induced mirror syndrome associated with elevated levels of angiogenic factors. Obstet Gynecol 2007; 109 (5): 1205–6.
123.Koga, K, Osuga, Y, Tajima, T, Hirota, Y, Igarashi, T, Fujii, T, et al.Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. Fertil Steril 2009; 94 (1): 305–8.
124.Soto-Wright, V, Bernstein, M, Goldstein, DP, Berkowitz, RS. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol 1995; 86 (5): 775–9.
125.Jauniaux, E. Partial moles: from postnatal to prenatal diagnosis. Placenta 1999; 20 (5–6): 379–88.
126.Prasannan-Nair, C, Reynolds, SF, Budden, G. Partial molar pregnancy with severe pre-eclampsia at 19 weeks’ gestation. J Obstet Gynaecol 2006; 26 (8): 817.
127.Stefos, T, Plachouras, N, Mari, G, Cosmi, E, Lolis, D. A case of partial mole and atypical type I triploidy associated with severe HELLP syndrome at 18 weeks’ gestation. Ultrasound Obstet Gynecol 2002; 20 (4): 403–4.
128.Sherer, DM, Dalloul, M, Stimphil, R, Hellmann, M, Khoury-Collado, F, Osho, J, et al.Acute onset of severe hemolysis, elevated liver enzymes, and low platelet count syndrome in a patient with a partial hydatidiform mole at 17 weeks gestation. Am J Perinatol 2006; 23 (3): 163–6.
129.Jank, A, Kratzsch, J, Stepan, H. Effect of terminated fetal circulation on maternal angiogenic factors in severe early preeclampsia. Hypertens Pregnancy 2012.
130.Benirschke, K, Kaufmann, P, Baergen, R. Molar pregnancies. In: Benirschke, K, Kaufmann, P, Baergen, R (eds.) Pathology of the Human Placenta. New York, NY: Springer, 2006; 797–836.
131.Qiao, S, Nagasaka, T, Nakashima, N. Numerous vessels detected by CD34 in the villous stroma of complete hydatidiform moles. Int J Gynecol Pathol 1997; 16 (3): 233–8.
132.Sibai, BM, Stella, CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009; 200 (5): 481–7.
133.Burton, GJ, Charnock-Jones, DS, Jauniaux, E. Regulation of vascular growth and function in the human placenta. Reproduction 2009; 138 (6): 895–902.
134.Espinoza, J, Espinoza, AF. Pre-eclampsia: a maternal manifestation of a fetal adaptive response? Ultrasound Obstet Gynecol 2011; 38 (4): 367–70.
135.Espinoza, J, Espinoza, AF, Power, GG. High fetal plasma adenosine concentration: a role for the fetus in preeclampsia? Am J Obstet Gynecol 2011; 205 (5): 485.e24-7.
136.Jeyabalan, A, McGonigal, S, Gilmour, C, Hubel, CA, Rajakumar, A. Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta 2008; 29 (6): 555–63.
137.Lin, S, Shimizu, I, Suehara, N, Nakayama, M, Aono, T. Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol 1995; 85 (5, Pt 1): 760–5.
138.Olofsson, P, Laurini, RN, Marsal, K. A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol 1993; 49 (3): 161–8.
139.Aardema, MW, Oosterhof, H, Timmer, A, van, R, I, Aarnoudse, JG. Uterine artery Doppler flow and uteroplacental vascular pathology in normal pregnancies and pregnancies complicated by pre-eclampsia and small for gestational age fetuses. Placenta 2001; 22 (5): 405–11.
140.Madazli, R, Somunkiran, A, Calay, Z, Ilvan, S, Aksu, MF. Histomorphology of the placenta and the placental bed of growth restricted foetuses and correlation with the Doppler velocimetries of the uterine and umbilical arteries. Placenta 2003; 24 (5): 510–16.
141.Voigt, HJ, Becker, V. Doppler flow measurements and histomorphology of the placental bed in uteroplacental insufficiency. J Perinat Med 1992; 20 (2): 139–47.
142.Espinoza, J, Romero, R, Mee, KY, Kusanovic, JP, Hassan, S, Erez, O, et al.Normal and abnormal transformation of the spiral arteries during pregnancy. J Perinat Med 2006; 34 (6): 447–58.
143.Pijnenborg, R, Vercruysse, L, Hanssens, M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta 2006; 27 (9–10): 939–58.
144.Kosaka, K, Fujiwara, H, Yoshioka, S, Fujii, S. Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome. Hum Reprod 2007; 22 (6): 1647–51.
145.Pau, E, Alonso-Muriel, I, Gomez, R, Novella, E, Ruiz, A, Garcia-Velasco, JA, et al.Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod 2006; 21 (6): 1453–60.
146.Gomez, R, Simon, C, Remohi, J, Pellicer, A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod 2003; 68 (6): 2164–71.
147.Gomez, R, Simon, C, Remohi, J, Pellicer, A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002; 143 (11): 4339–48.
148.Luttun, A, Tjwa, M, Carmeliet, P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann N Y Acad Sci 2002; 979: 80–93.
149.Li, Z, Zhang, Y, Ying, MJ, Kapoun, AM, Shao, Q, Kerr, I, et al.Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007; 50 (4): 686–92.
150.Thadhani, R, Kisner, T, Hagmann, H, Bossung, V, Noack, S, Schaarschmidt, W, et al.Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase-1 in preeclampsia. Circulation 2011; 124 (8): 940–50.